Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection

European Journal of Clinical Pharmacology

Volumn 69, Issue 7, 2013, Pages 1429-1436

  Karnik, Niteen D ^a   Sridharan, Kannan ^a   Jadhav, Sonali P ^b   Kadam, Prashant P ^a   Naidu, Raghu K ^c   Namjoshi, Rahul D ^b   Gupta, Vishal ^a   Gore, Mangesh S ^a   Surase, Pallavi V ^a   Mehta, Preeti R ^a   Gogtay, Jaideep A ^b   Thatte, Urmila M ^a   Gogtay, Nithya J ^a  

^a KEM HOSPITAL   (India)

^b CIPLA LTD   (India)

^c Sitec Laboratories Pvt Ltd   (India)

Author keywords

Colistimethate sodium; Multidrug resistant Gram negative bacilli; Pharmacokinetics; Single dose; Steady state

Indexed keywords

COLISTIMETHATE;

ACINETOBACTER; ADOLESCENT; ADULT; ARTICLE; BACTERIUM CULTURE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONVULSION; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPONATREMIA; INTENSIVE CARE UNIT; KIDNEY FUNCTION; LEG PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS; TERTIARY HEALTH CARE;

ACINETOBACTER; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INDIA; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; KIDNEY; KLEBSIELLA PNEUMONIAE; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS; RENAL INSUFFICIENCY; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84879126671     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1493-9     Document Type: Article

References (33)

1. D'Agata EMC (2004) Rapidly rising prevalence of nosocomial multidrug resistant, Gram negative bacilli: a 9 year surveillance study. Infect Control Hosp Epidemiol 25:842-846
2. Doughlas MW, Mulholland K, Denyer V et al (2001) Multidrug resistant Pseudomonas aeruginosa outbreak in a burns unit - an infection control study. Burns 7:131-135
3. Livermore DM (2002) Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: or worst nightmare? Clin Infect Dis 34:634-640
4. Li J, Nation RI, Milne RW, Turnidge JD et al (2005) Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 25:11-25
5. Livermore DM (2004) The need for new antibiotics. Clin Microbiol Infect 10(4):1-9
6. Li J, Nation RL, Turpidge JD et al (2006) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589-601
7. Landman D, Georgescu C, Martin DA et al (2008) Polymyxins revisited. Clin Microbiol Rev 21:449-465
8. Durakovic N, Radojcic V, Boban A et al (2011) Efficacy and safety of colistin in the treatment of infections caused by multi-drug resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med 50:1009-1013
9. Orwa JA, Govaerts R, Busson R et al (2001) Isolation and structural characterization of colistin components. J Antibiot (Tokyo) 54:595-599
10. Owen RJ, Li J, Nation RL et al (2007) In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 59:473-477
11. Li J, Turnidge J, Milne R et al (2001) In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 45:781-785
12. Koomanachai P, Tiengrim S, Kiratisin et al (2007) Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj hospital, Bangkok, Thailand. Int J Infect Dis 11:402-406
13. Pintado V, Miguel LGS, Grill F et al (2008) Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria. J Infect 56:185-190
14. Hachem RY, Chemaly RF, Ahmar CA et al (2007) Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer subjects. Antimicrob Agents Chemother 51:1905-1911
15. European Committee on Antimicrobial Susceptibility Testing. Miscellaneous antimicrobials - EUCAST clinical MIC breakpoints 2009-12-13 (v 2.3). Available at: www.srga.org/eucastwt/MICTAB/MICmiscellaneous.html. Accessed 2 Feb 2012
16. Nation RL, Li J (2007) Optimizing use of colistin and polymyxin B in the critically ill. Semin Respir Crit Care Med 28:604-614
17. Li J, Coulthard K, Milne R et al (2003) Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 52:987-992
18. Markou N, Markantonis SL, Dimitrakis E et al (2008) Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug resistant, Gram negative bacilli infections: a prospective, open label, uncontrolled study. Clin Ther 30:143-151
19. Ratjen F, Rietschel E, Kasel D et al (2006) Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 57:306-311
20. Imberti R, Cusato M, Villani P et al (2010) Steady-state pharmacokinetics and bronchoalveolar lavage concentration of colistin in critically ill patients after intravenous colistin methanesulphonate administration. Chest 138:1333-1339
21. Reed MD, Stern RC, O'Riordan MA et al (2001) The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 41:645-654
22. Giske CG, Monnet DL, Cars O et al (2008) Clinical and economic impact of common multidrug-resistant Gram negative bacilli. Antimicrob Agents Chemother 52:813-821
23. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Available at: http://www.kidney.org/ professionals/kdoqi/guidelines-ckd/p4-class-g1.htm. Accessed 26 Nov 2012
24. Ma Z, Wang J, Gerber JP et al (2008) Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS. J Chromatogr B 862:205-212
25. Sabuda DM, Laupland K, Pitout J et al (2008) Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol 19:413-418
26. Florescu DF, Qiu F, McCartan MA et al (2012) What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 54:670-680
27. Mehrotra R, Gaudie RD, Palazzo M (2004) Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 30:2145-2156
28. Li J, Rayner CR, Nation RL et al (2006) Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50:2946-2950
29. De Gaudio AR, Rinaldi S, Adembri C (2012) Systemic antibiotics. In: Van Saene HKF, Silvestri L, Del la Cal MA, Gullo A (eds) Infection control in the intensive care unit. Springer SBM, Milan, p 73
30. Levison ME (2004) Pharmacodynamics of antimicrobial drugs. Infect Dis Clin North Am 18:451-465
31. Couet W, Gregoire N, Marchand S et al (2012) Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect 18:30-39
32. Plachouras D, Karvanen M, Friberg LE et al (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram negative bacteria. Antimicrob Agents Chemother 53:3430-3436
33. Mohamed AF, Karaiskos I, Plachouras D et al (2012) Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56:4241-4249